Third Dose of COVID-19 Vaccinations for Immunocompromised People

ATAGI has recommended that immunocompromised patients, including people with an active haematological malignancy, receive a 3rd primary dose of a COVID-19 vaccine. This includes all patients with myelodysplasia, leukaemia (acute or chronic), myeloproliferative neoplasms, myeloma and lymphoma. A 3rd dose of an mRNA vaccine (e.g. Pfizer or Moderna) should be administered between 2 and 6 months after the 2nd dose. Central Coast Haematology recommend proceeding with this as soon as it can be arranged within the time-frame recommended. 

Transplant patients require revaccination with 3 additional doses of a COVID-19 vaccine commencing >3-6 months post transplant.